Calliditas Therapeutics AB (publ)
Stock Forecast, Prediction & Price Target
Calliditas Therapeutics AB (publ) Financial Estimates
Calliditas Therapeutics AB (publ) Revenue Estimates
Calliditas Therapeutics AB (publ) EBITDA Estimates
Calliditas Therapeutics AB (publ) Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $229.34M N/A | $802.87M 250.07% | $1.20B 50.32% | Avg: $3.35B Low: $2.75B High: $4.41B avg. 178.18% | Avg: $4.70B Low: $4.16B High: $5.75B avg. 40.12% | Avg: $6.12B Low: $5.41B High: $7.48B avg. 30.15% | Avg: $7.67B Low: $6.79B High: $9.39B avg. 25.40% |
Net Income
% change YoY
| $-509.53M N/A | $-412.26M 19.08% | $-466.18M -13.07% | Avg: $1.74B Low: $775.71M High: $3.05B avg. 473.87% | Avg: $3.02B Low: $2.56B High: $3.89B avg. 73.31% | Avg: $4.20B Low: $3.57B High: $5.42B avg. 39.18% | Avg: $5.77B Low: $4.91B High: $7.44B avg. 37.30% |
EBITDA
% change YoY
| $-524.45M N/A | $-421.94M 19.54% | $-367.80M 12.83% | Avg: $-1.99B Low: $-2.62B High: $-1.63B avg. -441.53% | Avg: $-2.79B Low: $-3.41B High: $-2.47B avg. -40.12% | Avg: $-3.63B Low: $-4.44B High: $-3.21B avg. -30.15% | Avg: $-4.55B Low: $-5.57B High: $-4.03B avg. -25.40% |
EPS
% change YoY
| -$10.02 N/A | -$7.78 22.35% | -$8.69 -11.69% | Avg: $32.47 Low: $14.45 High: $56.92 avg. 473.69% | Avg: $56.28 Low: $47.87 High: $72.61 avg. 73.31% | Avg: $78.34 Low: $66.63 High: $101.06 avg. 39.18% | Avg: $107.56 Low: $91.49 High: $138.76 avg. 37.30% |
Operating Expenses
% change YoY
| $753.80M N/A | $1.20B 60.46% | $1.51B 25.18% | Avg: $111.46B Low: $91.47B High: $146.67B avg. 7261.39% | Avg: $156.19B Low: $138.23B High: $191.04B avg. 40.12% | Avg: $203.28B Low: $179.91B High: $248.64B avg. 30.15% | Avg: $254.92B Low: $225.62B High: $311.81B avg. 25.40% |
FAQ
What is Calliditas Therapeutics AB (publ) stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 155.92% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is 775.71M, average is 1.74B and high is 3.05B.
What is Calliditas Therapeutics AB (publ) stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 68.46% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $2.75B, average is $3.35B and high is $4.41B.
What is Calliditas Therapeutics AB (publ) stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 155.87% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is $14.45, average is $32.47 and high is $56.91.
What is the best performing analyst?
In the last twelve months analysts have been covering Calliditas Therapeutics AB (publ) stock. The most successful analyst is Annabel Samimy.